source
- BioNTech’s mRNA cancer vaccine misses key endpoint in head-and-neck trial, study to continueBioNTech reported that its mRNA cancer immunotherapy BNT113 did not improve progression‑free survival when added to Keytruda in patients with HPV16‑positive head and neck squamous cell carcinoma. T…
- Roche licenses Rona's ALK7 obesity candidate in $1.2 billion dealRoche has agreed to license an RNAi drug candidate targeting ALK7 from Chinese biotech Rona Therapeutics, with an upfront payment of $100 million and potential milestones up to $1.06 billion. The…